116 related articles for article (PubMed ID: 22078205)
21. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
22. Oral contraceptives and blood coagulation.
Bonnar J; Sabra AM
J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
[TBL] [Abstract][Full Text] [Related]
23. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
[No Abstract] [Full Text] [Related]
24. Clinical trial of an oral contraceptive containing desogestrel and ethinyl estradiol.
Weijers MJ
Clin Ther; 1982; 4(5):359-66. PubMed ID: 6461412
[TBL] [Abstract][Full Text] [Related]
25. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
Benagiano G
Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
[TBL] [Abstract][Full Text] [Related]
26. [The desogestrel-ethinyl estradiol combination and overweight: current data].
Rubio Lotvin B
Ginecol Obstet Mex; 1995 Nov; 63():483-6. PubMed ID: 8537039
[TBL] [Abstract][Full Text] [Related]
27. Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight.
Dieben TO; van Beek A; Coelingh Bennink HJ
Arzneimittelforschung; 1991 Sep; 41(9):996-8. PubMed ID: 1839126
[TBL] [Abstract][Full Text] [Related]
28. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
Klipping C; Marr J
Contraception; 2005 Jun; 71(6):409-16. PubMed ID: 15914128
[TBL] [Abstract][Full Text] [Related]
29. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Dieben TO; op ten Berg MT; Coelingh Bennink HJ
Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
[TBL] [Abstract][Full Text] [Related]
30. Renewed interest in haemostasis changes induced by oral contraceptives (OCs).
Kluft C
Thromb Haemost; 2000 Jul; 84(1):1-3. PubMed ID: 10928460
[No Abstract] [Full Text] [Related]
31. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
32. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with an ethinyl estradiol-desogestrel oral contraceptive.
Van Trappen Y; Duvivier P; Thiery M; Van Kets H; Defoort P; Parewijck W; Derom R; Kermans G; Schoofs P
Arzneimittelforschung; 1989 Jun; 39(6):717-9. PubMed ID: 2528355
[TBL] [Abstract][Full Text] [Related]
34. Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in human preeclamptic placenta: possible implications in the process of trophoblast apoptosis.
Lee H; Park H; Kim YJ; Kim HJ; Ahn YM; Park B; Park JH; Lee BE
Placenta; 2005; 26(2-3):226-33. PubMed ID: 15708124
[TBL] [Abstract][Full Text] [Related]
35. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
Vree ML; Schmidt J
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
[TBL] [Abstract][Full Text] [Related]
36. Effects of hormonal contraception on bone mineral density after 24 months of use.
Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
[TBL] [Abstract][Full Text] [Related]
37. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII.
van Rooijen M; von Schoultz B; Silveira A; Hamsten A; Bremme K
Am J Obstet Gynecol; 2002 Jan; 186(1):44-8. PubMed ID: 11810082
[TBL] [Abstract][Full Text] [Related]
38. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
39. Effects of two low-dose oral contraceptives on erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities.
Jendryczko A; Tomala J; Janosz P
Zentralbl Gynakol; 1993; 115(11):469-72. PubMed ID: 8296490
[TBL] [Abstract][Full Text] [Related]
40. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
